Literature DB >> 7622424

Effects of methylxanthine derivatives on adriamycin concentration and antitumor activity.

Y Sadzuka1, A Iwazaki, A Miyagishima, Y Nozawa, S Hirota.   

Abstract

We studied the mechanism whereby caffeine acts as a biochemical modulator of adriamycin, and examined various methylxanthine derivitives to determine whether they would be of value as biochemical modulators. In an in vitro study of adriamycin efflux in Ehrlich ascites carcinoma cells, theophylline, pentoxifylline, and theobromine inhibited this efflux, while caffeine metabolites did not. The effects of several methylxanthine derivatives on the antitumor activity of adriamycin and on adriamycin concentration in tissue were also examined in CDF1 tumor-bearing mice. Theobromine, which inhibited adriamycin efflux in vitro, increased the antitumor activity of adriamycin and the concentration of adriamycin in tumors. The caffeine metabolites, which had no effect on the adriamycin efflux, did not increase antitumor activity. These results suggest that the metabolism of caffeine may weaken its effect as a biochemical modulator, and that pentoxifylline and theobromine would be of value as biochemical modulators of adriamycin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622424      PMCID: PMC5920866          DOI: 10.1111/j.1349-7006.1995.tb02439.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  19 in total

1.  Potentiation of cisplatin cytotoxicity by methylxanthines in vitro.

Authors:  E Petru; G Boike; B U Sevin
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Inhibition of DNA biosynthesis by vincristine and pentoxifylline in murine P388 leukemia cells resistant to doxorubicin.

Authors:  M P Chitnis; A B Viladkar; A S Juvekar
Journal:  Neoplasma       Date:  1990       Impact factor: 2.575

3.  Pentoxifylline and other methyl xanthines inhibit interleukin-2 receptor expression in human lymphocytes.

Authors:  K M Rao; M S Currie; S S McCachren; H J Cohen
Journal:  Cell Immunol       Date:  1991-07       Impact factor: 4.868

4.  Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies.

Authors:  D M Grant; M E Campbell; B K Tang; W Kalow
Journal:  Biochem Pharmacol       Date:  1987-04-15       Impact factor: 5.858

5.  Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease.

Authors:  A M Ehrly
Journal:  Angiology       Date:  1976-03       Impact factor: 3.619

6.  Differential reduction by caffeine of adriamycin induced cell killing and cell cycle delays in Chinese hamster V79 cells.

Authors:  G Iliakis; M Nusse; R Ganapathi; J Egner; A Yen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-11       Impact factor: 7.038

7.  Caffeine enhances adriamycin antitumor activity in Ehrlich ascites carcinoma-bearing mice.

Authors:  Y Sadzuka; E Mochizuki; A Iwazaki; S Hirota; Y Takino
Journal:  Biol Pharm Bull       Date:  1995-01       Impact factor: 2.233

8.  Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents.

Authors:  G D Martich; R L Danner; M Ceska; A F Suffredini
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

9.  Caffeine enhancement of the effect of anticancer agents on human sarcoma cells.

Authors:  K Tomita; H Tsuchiya
Journal:  Jpn J Cancer Res       Date:  1989-01

10.  Caffeine modulates the antitumor activity and toxic side effects of adriamycin.

Authors:  Y Sadzuka; E Mochizuki; Y Takino
Journal:  Jpn J Cancer Res       Date:  1993-03
View more
  4 in total

1.  Spectral analysis of naturally occurring methylxanthines (theophylline, theobromine and caffeine) binding with DNA.

Authors:  Irudayam Maria Johnson; Halan Prakash; Jeyaguru Prathiba; Raghavachary Raghunathan; Raghunathan Malathi
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

2.  Effects of 1-methyl-3-propyl-7-butylxanthine (MPBX) on idarubicin-induced antitumor activity and bone marrow suppression.

Authors:  Y Sadzuka; Y Egawa; T Sugiyama; H Sawanishi; K Miyamoto; T Sonobe
Journal:  Jpn J Cancer Res       Date:  2000-06

3.  1-Methyl-3-propyl-7-butylxanthine, a novel biochemical modulator, enhances therapeutic efficacy of adriamycin.

Authors:  Y Sadzuka; A Iwazaki; T Sugiyama; T Sawanishi; K Miyamoto
Journal:  Jpn J Cancer Res       Date:  1998-02

Review 4.  Xanthine scaffold: scope and potential in drug development.

Authors:  Nivedita Singh; Ashwinee Kumar Shreshtha; M S Thakur; Sanjukta Patra
Journal:  Heliyon       Date:  2018-10-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.